Browse by category

FDA approves Wegovy for CVD risk reduction in people with overweight or obesity and established cardiovascular disease

The FDA has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing...

FLOW trial: Semaglutide 1.0mg demonstrates 24% reduction in the risk of kidney disease-related events in T2DM and chronic kidney disease patients

Headline results from the kidney outcomes trial FLOW (Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in...

Novo Nordisk to end semaglutide kidney study early due to strong efficacy signals

Novo Nordisk is ending its Phase III FLOW trial ahead of schedule after an interim analysis of the kidney outcomes study of semaglutide...

Study links GLP-1s with serious gastrointestinal conditions

Glucagon-like peptide-1 (GLP-1) agonists are associated with an increased risk of serious medical conditions including stomach paralysis,...

Rejuva GLP-1-based pancreatic gene therapy candidate results in greater weight loss vs. semaglutide

Fractyl Health has revealed preclinical findings from its Rejuva gene therapy platform at the European Association for the Study of...

Journal Watch 4/10/2023

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Tirzepatide more effective in blood sugar control and body weight loss than semaglutide

A new meta-analysis combining 22 studies shows that tirzepatide is superior to semaglutide for both control of blood sugar and in terms...

Journal Watch 16/08/2023

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

SELECT trial: Semaglutide reduces the risk of MACE by 20% in adults with overweight or obesity

Results from the SELECT cardiovascular outcomes trial has revealed that semaglutide 2.4mg demonstrated a statistically significant and...

EMA reviewing data after reports of suicidal thoughts and thoughts of self-harm after taking GLP-1a

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) is reviewing data on the risk of suicidal...

Ratioing the resected gastric volume to the number of fired staplers predicts weight loss

6 days ago

Arrowhead initiates phase 1/2a study of ARO-INHBE for obesity

6 days ago

Survey finds 93.4% of bariatric patients vs 51.4% of GLP-1 patients have the same treatment again

Dec 26, 2024

Weekly Digest